

**No. 31015/80/2017-Pricing
GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS & FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS**

.....

A- Wing, Shastri Bhawan,
New Delhi 110 001

Subject: Review application of M/s Amanta Healthcare Limited against price fixation of "Ringer Lactate Injection" vide NPPA order No. S.O. 2401(E), dated 28.07.2017 issued under Drugs (Prices Control) Order, 2013 (DPCO 2013).

Ref: 1) Review application dated 17.08.2017
2) NPPA notification under review S.O. 2401(E), dated 28.07.2017

1. This is a petition under paragraph 31 of the Drugs (Prices Control) Order, 2013 (hereinafter called the DPCO) filed by M/s Amanta Healthcare Limited (hereinafter called the petitioner) against notification S.O. No.2401(E), dated 28.07.2017 issued by the National Pharmaceutical Pricing Authority (hereinafter called the NPPA) fixing the ceiling price of Ringer Lactate Injection.

2. A personal hearing was fixed for 5.12.2017 to the company. However, Company vide its email dated 5.12.2017 stated that due to unavoidable circumstances, they could not attend the hearing and requested for some other date with the commitment to definitely attend the hearing. Accordingly, the hearing was rescheduled and company was asked vide letter dated 7.12.2017 to appear for personal hearing on 12.12.2017. In spite of that, the representatives of the petitioner company did not attend the hearing. Hence, the proceedings were held ex-parte.

3. As per information available with NPPA (through IPDMS report), company has not been following ceiling price notified vide S.O. 2401(E) dated 28.07.2017 for the above mentioned formulation. Para 31 of DPCO, 2013 states that "*.....pending a decision by the Government on the application submitted under the above paragraph, no manufacturer shall sell a scheduled formulation or a new drug, as the case may be, at a price exceeding the ceiling price or retail price, as the case may be, fixed by the Government of which a review has been applied for.*" Since there is no documentary evidence in regard to compliance of notified price by the company, the review application may be rejected.

4. **Government Decision:**

"In the absence of any documentary evidence available in the records with NPPA in regard to compliance of notified price of Ringer Lactate Injection by the company, as per provisions under para 31 of DPCO, 2013, the review application stands rejected."

Issued on this date, the 10th day of January, 2018.

(M.K. Bhardwaj)
Deputy Secretary
For and on behalf of the President of India

To

1. M/s. Amanta Healthcare Limited,
5th Floor, Heritage, Nr.Gujarat Vidhyapith,
Ashram Road,
Ahmedabad-380 014.
2. The Member Secretary,
National Pharmaceutical Pricing Authority,
YMCA Cultural Centre Building, New Delhi-110001

Copy to :

1. PS to Hon'ble Minister (C&F), Shastri Bhawan, New Delhi for information.
2. PSO to Secretary (Pharma), Shastri Bhawan, New Delhi for information.
3. T.D., NIC for uploading the order on Department's Website